Cargando…

Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries

INTRODUCTION: The current study describes real-world clinical outcomes and factor usage among patients with haemophilia B switching from standard half-life factor IX (SHL FIX) treatment to recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis in European treatment centres. METHODS: This non-i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Funding, Eva, Lowe, Gillian, Poulsen, Lone H., Shapiro, Susan, Oldenburg, Johannes, Eriksson, Daniel, Falk, Aletta, Rich, Carly
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427542/ https://www.ncbi.nlm.nih.gov/pubmed/37351812 http://dx.doi.org/10.1007/s12325-023-02559-1

Ejemplares similares

Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B
por: Aiello, Andrea, et al.
Publicado: (2020)

Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B
por: Diao, Lei, et al.
Publicado: (2014)

Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials
por: Mancuso, Maria Elisa, et al.
Publicado: (2023)

Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B
por: Miguelino, Maricel G, et al.
Publicado: (2014)

Real‐world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years
por: Shapiro, Amy, et al.
Publicado: (2020)

Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study
por: Simpson, Mindy L, et al.
Publicado: (2019)

Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials
por: Astermark, Jan, et al.
Publicado: (2021)

Bleeding outcomes and factor utilization after switching to an extended half-life product for prophylaxis in haemophilia A in Austria
por: Ay, Cihan, et al.
Publicado: (2021)

Cardiovascular disease in hereditary haemophilia: The challenges of longevity
por: Shapiro, Susan, et al.
Publicado: (2022)

Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study
por: Kenet, Gili, et al.
Publicado: (2021)

Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand
por: Oldenburg, J, et al.
Publicado: (2015)

Haemophilia A: Pharmacoeconomic Review of Prophylaxis Treatment versus On-Demand
por: Unim, Brigid, et al.
Publicado: (2015)

Medication Adherence for Haemophilia Patients: Outcome of Prophylaxis Treatment Intervention
por: Mokhtar, Fadzlin Mohd, et al.
Publicado: (2021)

Switching treatments in haemophilia: is there a risk of inhibitor development?
por: Santagostino, Elena, et al.
Publicado: (2015)

Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life?
por: Allard, Quentin, et al.
Publicado: (2020)

A new paradigm for personalized prophylaxis for patients with severe haemophilia A
por: Delavenne, Xavier, et al.
Publicado: (2020)

Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Personalised Prophylaxis in a Child with Haemophilia A and Type 1 Diabetes
por: Cruz, Maria Sol, et al.
Publicado: (2021)

COVID-19 prophylaxis: half-full or half-empty glass?
por: Scarfò, Lydia, et al.
Publicado: (2023)

High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Hæmophilia
Publicado: (1905)

Hæmophilia
por: Ruggles, S. D.
Publicado: (1902)

Hæmophilia
por: Porter, Charles A.
Publicado: (1900)

Quality of life in a large multinational haemophilia B cohort (The B‐Natural study) – Unmet needs remain
por: Berntorp, Erik, et al.
Publicado: (2022)

Adherence to Prophylaxis in Adolescents and Young Adults with Severe Haemophilia: A Quantitative Study with Patients
por: van Os, Sandra B., et al.
Publicado: (2017)

The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies
por: Skinner, Mark W., et al.
Publicado: (2021)

Safety of intramuscular COVID‐19 vaccination in patients with haemophilia
por: Tiede, Andreas, et al.
Publicado: (2022)

S300: ASSESSMENT OF JOINT HEALTH IN PATIENTS RECEIVING PROPHYLAXIS FOR HAEMOPHILIA A IN FIVE EUROPEAN COUNTRIES: A CROSS-SECTIONAL SURVEY
por: De la Corte‐rodriguez, Hortensia, et al.
Publicado: (2023)

Pain, depression and anxiety in people with haemophilia from three Nordic countries: Cross‐sectional survey data from the MIND study
por: Steen Carlsson, Katarina, et al.
Publicado: (2022)

Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
por: Mahlangu, Johnny N.
Publicado: (2018)

Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update
por: Aiello, Andrea, et al.
Publicado: (2022)

European principles of inhibitor management in patients with haemophilia
por: Giangrande, P. L. F., et al.
Publicado: (2018)

Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors
por: Antunes, S V, et al.
Publicado: (2014)

BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
por: Santoro, Cristina, et al.
Publicado: (2020)

Adherence to prophylaxis in adolescents and young adults with severe haemophilia: a qualitative study with healthcare professionals
por: van Os, S., et al.
Publicado: (2020)

Adherence to prophylaxis in adolescents and young adults with severe haemophilia A, a qualitative study with patients
por: van Os, S., et al.
Publicado: (2018)

Legg on Hæmophilia
Publicado: (1873)

Malarious Hæmophilia
Publicado: (1890)

The Treatment of Haemophilia
por: Biggs, Rosemary
Publicado: (1969)

Living with Haemophilia
por: Laffan, Mike
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_knsgilt0s1vs4hgeieu04fqgpk